Why This Biotech Fund Increased Its Oruka Stake Amid a 500% Rally
A biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
This article compares Zero Based Budgeting and Incremental Budgeting, showing practical differences, use cases, and potential impacts on your budget.
18,304 articlesA biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
The CLARITY Act fight over crypto ethics stalled as lawmakers clashed on enforcement and state powers, leaving invest...
TIAA's leader recalls starting with a modest $26,000 salary and still maxing out her 401(k), underscoring the long-te...
Two big catalysts could push XP stock higher: regulatory clarity in Brazil’s fintech scene and stronger cross-selling...
A respected Wall Street voice argues for a bold bitcoin target. This guide breaks down the reasoning, checks the math...
Two ad-tech leaders with different business models, The Trade Desk and AppLovin, reveal distinct quarterly revenue pa...
As quantum tech evolves, investors wonder where will rigetti computing end up by 2030. This article breaks down miles...
Beyond Meat once drew huge hype, but the stock has faced major headwinds. This article breaks down three concrete rea...
Navigate Neptune's Q4 2025 performance, understand margin dynamics, and gauge 2026 guidance. This practical guide exp...
A focused look at OmniAb's Q4 2025 earnings and what the numbers could mean for investors. Discover the drivers, risk...
VR Adviser recently disclosed a substantial sale of Ocular Therapeutix shares, triggering questions about what it mea...
A geopolitical chokepoint isn't just about oil. The Strait of Hormuz also moves a vital portion of global fertilizer....